GRI - GRI Bio, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

GRI

GRI BIO, INC.

NASDAQ

$1.92

▼ DOWN 7.25% (-0.15)

KEY STATISTICS

Market Cap$172.48 K

52w High$80.36

52w Low$1.36

Dividend Yield0.00%

FrequencyIrregular

P/E-0.04

Volume33.45K

Shares Out.89.83K

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

W. Marc Hertz

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 10, 2021

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 13, 2026

DayFriday

Rev. Est.—

NOV

FRI

SPLIT RECORD

DATE	TYPE	RATIO
2026-01-26	Reverse	1:28
2025-02-24	Reverse	1:17
2024-06-18	Reverse	1:13
2024-01-30	Reverse	1:7
2023-04-24	Reverse	1:30

PRICE

$1.92 ▼ DOWN 7.25% (−$0.15)

OVERLAYS

About GRI Bio, Inc.

https://www.gribio.com ↗

GRI Bio, Inc. is a clinical-stage biopharmaceutical company developing therapies targeting inflammatory, fibrotic, and autoimmune diseases, with lead candidates GRI-0621 in phase IIa for fibrotic lung diseases.

INDUSTRY

Biotechnology

A PRODUCT GRI BIO, INC. IS KNOWN FOR

GRI-0621

GRI-0621 is a clinical-stage oral therapy by GRI Bio targeting idiopathic pulmonary fibrosis by inhibiting NKT cells to modulate immune response and reduce inflammation and fibrosis.